Drug Addiction Clinical Trial
Official title:
Effects of MDMA on Social and Emotional Processing
The main aim of the study is to investigate the effects of ±3,4-methylenedioxymethamphetamine (MDMA; ecstasy) on social and emotional processing in healthy humans. Ecstasy is a widely used recreational drug, with over 2 million Americans reporting use of the drug in 2006. With this number of users, and evidence that high doses of MDMA are neurotoxic in laboratory animals, the public health implications of ecstasy use may be substantial. Certain subjective effects of this drug distinguish it from other stimulants, and may contribute to its widespread use: That is, users report that ecstasy produces profound feelings of empathy and closeness to others. These so-called 'empathogenic' effects, which may reflect the distinctive neurochemical profile of action of the drug, have yet to be characterized in controlled laboratory studies. The investigators propose to characterize the effects of MDMA on measures of social and emotional processing that may contribute to this 'empathogenic' profile, including measures of emotion recognition, emotional responsiveness and sociability. The investigators will assess effects of MDMA (0, 0.75 and 1.5 mg/kg up to 125 mg) one active control drug (oxytocin: 20 IU) in 100 volunteers who report some prior ecstasy use. Oxytocin will be used because it appears to produce pro-social behavioral effects resembling those attributed to MDMA.
n/a
Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02192931 -
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
|
Phase 4 | |
| Completed |
NCT02437123 -
The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs
|
N/A | |
| Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
| Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
| Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
| Completed |
NCT01685073 -
The Role of Sleep in the Treatment of Cannabis Use Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT01591239 -
Home-Based Program to Help Parents of Drug Abusing Adolescents
|
N/A | |
| Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
| Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A | |
| Completed |
NCT04105621 -
Westlake Personalized Nutrition and Health Cohort for Drug Addicts
|
||
| Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
| Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
| Completed |
NCT00244699 -
Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth
|
N/A | |
| Completed |
NCT00496990 -
Treating the Partners of Drug Using Pregnant Women: Stage II
|
Phase 2/Phase 3 | |
| Completed |
NCT00390559 -
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
|
N/A | |
| Completed |
NCT03402672 -
AWAITS: A Web-based E-health Application for Active Illicit Opioid Users
|
N/A | |
| Completed |
NCT03411265 -
RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing
|
N/A | |
| Completed |
NCT01003496 -
Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial
|
Phase 3 | |
| Completed |
NCT02091167 -
Bilateral Prefrontal Modulation in Crack-cocaine Addiction
|
Phase 2 | |
| Completed |
NCT02091284 -
Bilateral Prefrontal Modulation in Alcoholism
|
N/A |